Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Macro

Trump Signs Executive Order to Lower Drug Prices and Address Medicare Policies

by Team Lumida
April 16, 2025
in Macro
Reading Time: 5 mins read
A A
0
$500 Billion Stargate AI Project Announcement Raises Funding Questions
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • President Trump signed an executive order aimed at reducing prescription drug prices, reviving policies from his first term, such as discounted insulin and epinephrine for uninsured and low-income patients at community health centers.
  • The order directs the Department of Health and Human Services (HHS) to address the “pill penalty” in the Inflation Reduction Act, which makes pills eligible for Medicare price negotiations after nine years, compared to 13 years for injected drugs.
  • The FDA has been instructed to streamline the drug importation program, initially introduced during Trump’s first term, to allow states to import lower-cost drugs more efficiently.
  • Trump also signed a memorandum to expand the Social Security Administration’s fraud prosecution program to prevent ineligible payments.

What Happened?

President Trump signed an executive order on Tuesday to lower prescription drug prices, focusing on Medicare beneficiaries and uninsured Americans. The order revives policies from his first administration, including a mandate for community health centers to provide discounted insulin and injectable epinephrine. This rule, rescinded by the Biden administration in 2021, is now back in effect.

The order also addresses the “pill penalty” in the Inflation Reduction Act, which has been criticized by the pharmaceutical industry for discouraging the development of pills. Pills become eligible for Medicare price negotiations after nine years on the market, while injected drugs have a 13-year timeline. The order directs HHS Secretary Robert F. Kennedy Jr. to work with Congress to equalize these timelines.

Additionally, the order calls for the FDA to streamline the drug importation program, which allows states to import lower-cost drugs under certain conditions. Florida is currently the only state with an approved program, but the order aims to make it easier for other states to gain approval.


Why It Matters?

The executive order reflects Trump’s ongoing focus on making prescription drugs more affordable, an issue that resonates with many Americans who believe drug prices are too high. By reviving policies like discounted insulin and addressing the “pill penalty,” the administration aims to reduce healthcare costs and encourage pharmaceutical innovation.

The streamlined drug importation program could provide states with access to lower-cost medications, potentially easing the financial burden on consumers. However, the success of these initiatives will depend on congressional action and the FDA’s ability to implement the changes effectively.

The expansion of the Social Security Administration’s fraud prosecution program also signals a broader effort to improve government efficiency and reduce wasteful spending.


What’s Next?

HHS will work with Congress to address the “pill penalty” and modify the Inflation Reduction Act, though legislative changes may face resistance from the pharmaceutical industry. The FDA will also need to act quickly to simplify the drug importation process and approve more state programs.

The broader impact of these measures on drug prices and healthcare costs will depend on how effectively they are implemented and whether Congress supports the proposed changes. Meanwhile, the Social Security Administration will ramp up efforts to prevent fraud and ensure benefits are distributed appropriately.

Source
Previous Post

J.B. Hunt Profit Drops Amid Weak Freight Demand and Tariff Uncertainty

Next Post

United Airlines Beats Expectations Despite Travel Demand Concerns and Economic Uncertainty

Recommended For You

Trump–Xi Truce Trades Rare-Earth Relief for Concessions, Easing Supply-Risk for U.S. Industry

by Team Lumida
15 hours ago
Trump–Xi Truce Trades Rare-Earth Relief for Concessions, Easing Supply-Risk for U.S. Industry

Key Takeaways Powered by lumidawealth.com Trump says Beijing will ease rare-earth export controls, removing a major supply chokepoint for EVs, wind, and defense. Concessions appear reciprocal: tariff relief and...

Read more

Fed to Cut Bank Supervision Staff by 30%, Signaling Softer Oversight

by Team Lumida
16 hours ago
Market Watch: Fed Holds Rates, Hints at September Cut”

Key Takeaways Powered by lumidawealth.com Headcount in Supervision & Regulation to drop from ~500 to ~350 by end-2026 via attrition and voluntary separations. Vice Chair for Supervision Michelle Bowman...

Read more

China’s PMI Slips to 49.0: Manufacturing Contraction Deepens Despite Services Stabilizing

by Team Lumida
16 hours ago
China’s Bold Economic Moves: What You Need to Know Now

Key Takeaways Powered by lumidawealth.com Official manufacturing PMI fell to 49.0 in October (Sep: 49.8), seventh straight month below 50. Export orders dropped to 45.9; production slid to 49.7;...

Read more

Trump Leans on Foreign Policy Wins as Domestic Pressures Mount

by Team Lumida
16 hours ago
Trump Tariffs Leave Key Questions on China Supply Chain Rules Unanswered

Key Takeaways Powered by lumidawealth.com Six-day Asia trip yielded trade pledges and investment MOUs; White House touts up to $2T in prospective commitments. Immediate U.S. backdrop: month-long government shutdown,...

Read more

Trump Cuts China Tariffs to Spur Fentanyl Crackdown and Trade De-escalation

by Team Lumida
2 days ago
Trump Announces 25% Tariffs on Mexico and Canada, Targeting Border Security and Trade

Key Takeaways Powered by lumidawealth.com U.S. lowers select China tariffs tied to fentanyl to 10% from 20%, nudging average tariffs on most Chinese imports to ~45% from ~55%. China...

Read more

Fed Seen Cutting Rates, But With No Added Signal

by Team Lumida
3 days ago
Why Mortgage Servicers Are Thriving Amid High Rates

Key Takeaways Fed expected to cut rates 25 bps Wednesday (2 p.m. decision, Powell presser 30 min later); Chair Powell likely to offer little guidance as growing divide...

Read more

After Demolishing the U.S.-China Relationship, Trump Is Rebuilding It His Way

by Team Lumida
3 days ago
Trump Tariffs Leave Key Questions on China Supply Chain Rules Unanswered

Key Takeaways Powered by lumidawealth.com U.S.-China trade negotiators reached framework agreement in Kuala Lumpur Sunday, setting stage for Trump-Xi deal Thursday in South Korea; transactional truce involves China resuming...

Read more

Trump Hails Golden Era in Japan Relations

by Team Lumida
3 days ago
Why Berkshire’s Latest Yen Bond Sale Could Ignite the Japanese Market

Key Takeaways Powered by lumidawealth.com Trump and new PM Takaichi pledged "golden age" of U.S.-Japan cooperation aboard USS George Washington; Takaichi vowed to boost defense spending to 2% of...

Read more

Rare Earths Producers Look to US-Led Boom to Blunt China’s Power

by Team Lumida
4 days ago
Rare Earths Producers Look to US-Led Boom to Blunt China’s Power

Key Takeaways Powered by lumidawealth.com US rare-earth magnet producers (Noveon, MP Materials) see surging demand after China's April export curbs; Adamas says US capacity could offset imports by 2028...

Read more

China Analysts Expect US to Ease Export Curbs for Magnet Relief

by Team Lumida
4 days ago
China’s Financial Overhaul: Xi’s Strategy to Rebalance $9.1 Trillion Debt Crisis

Key Takeaways Powered by lumidawealth.com Chinese analysts expect US to dial back Sept. 29 "affiliates rule" (restricting chip sales to subsidiaries of blacklisted Chinese firms like Huawei) in exchange...

Read more
Next Post
a united airlines plane flying in the sky

United Airlines Beats Expectations Despite Travel Demand Concerns and Economic Uncertainty

Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Nvidia Warns $5.5 Billion Loss as Trump Bans AI Chip Sales to China

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

grey and red flag

US-Sanctioned Russian LNG Tankers Head to Asia Seeking Buyers Amid Ukraine Talks

August 18, 2025
Bitcoin Could Drop to $50K Before a Potential Fed-Driven Rally

Bitcoin Surges as Altcoins Struggle in $300 Billion Crypto Market Shakeout

June 30, 2025
person grinding pipe steel wool photography

Trump Imposes 25% Tariffs on Steel and Aluminum Imports, Sparking Trade Tensions

February 10, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018